SelectQuote (SLQT) Q1 2027 Earnings Call Transcript

SelectQuote reported fiscal Q1 2027 revenue of $280 million, down 15% year over year, while its adjusted EBITDA loss improved by $15 million to $17 million. Healthcare Services adjusted EBITDA rose 56% to $11.2 million despite a 16% revenue decline, which management attributed mainly to Inflation Reduction Act drug-pricing effects; companywide operating cash flow was negative $17.2 million for the seasonally low quarter. Management reiterated fiscal 2027 guidance of $1.35 billion–$1.45 billion in revenue, $90 million–$115 million in adjusted EBITDA, and at least $60 million in operating cash flow, citing cost reductions and AI-enabled efficiency while prioritizing profitability over Senior policy volume.

Analysis

The earnings quality is improving faster than the growth profile: cost removal and a smaller, more seasoned agent base are supporting profit while policy volume and SelectRx membership contract. That is a credible near-term cash-preservation strategy, but it shifts equity value toward execution on retention and pharmacy productivity rather than a broad Medicare Advantage rebound. The 16% lift in policy LTV is not yet evidence of durable pricing power; management attributes it partly to carrier mix and CMS commission changes, both of which may not persist.

For the next several weeks, AEP engagement and carrier marketing decisions are the key swing factors. More carrier-directed outreach could add volume, but management says it raises acquisition costs, so incremental policies matter only if their lifetime value still clears CAC. Over 1–3 months, watch approved-policy volume and recapture against the prior-year baseline; early engagement commentary is not a substitute for realized enrollments. Over 6–18 months, the pharmacy system and migration of scripts to Olathe could create operating leverage, but the facility currently handles a small share of scripts and management’s margin-doubling expectation remains unverified. IRA-related revenue pressure may also continue through successive drug cohorts, making revenue growth a noisy signal of underlying economics.

The contrarian risk is that investors capitalize temporary cost cuts and seasonal cash generation as a durable earnings inflection while the business is still shrinking. Conversely, revenue declines may overstate economic damage where reimbursement offsets lower drug prices. The reverse split is not itself dilution, but the listing-maintenance rationale is a liquidity and confidence warning. Cash conversion, debt reduction, and the preferred-dividend path matter more than adjusted EBITDA alone.

Key Decisions for Investors

• No aggressive directional position before AEP conversion data. Treat SLQT as a high-risk watch; reassess after approved-policy volume, recapture, and acquisition economics become clearer.
• For a constructive entry, require evidence that the next enrollment season produces stable or improving policy volume without CAC deterioration, and that operating cash flow supports actual debt reduction—not just reiterated guidance. Falsify the thesis if cash conversion misses guidance or policy volumes fall materially short of management’s expectations.
• Monitor SelectRx member count and EBITDA per member alongside the share of prescriptions processed through Olathe. Do not underwrite the promised margin expansion until throughput rises and segment cash generation confirms it; migration delays or falling per-member economics weaken the case.
• Watch carrier marketing changes through late November: incremental demand is only positive if commission value and retention economics outweigh higher acquisition costs. Track any guidance revision and the preferred-dividend/debt trajectory as the key 1–3 quarter balance-sheet catalysts.